Global Companion Diagnostics Market Size, Share, Growth, Trends, and Forecast (2024 - 2031)
Global Companion Diagnostics Market Scope: Historical Data (2021 – 2022), Base Year (2023), Forecast Period (2024 – 2031)
Market Segmentation: By Technology (Immunohistochemistry (IHC), Polymerase Chain Reaction (PCR), In-situ Hybridization (ISH), Real-time PCR (RT-PCR), Gene Sequencing, and Other Technologies), Indication (Lung Cancer, Breast Cancer, Colorectal Cancer, Leukemia, Melanoma, and Other Indications), and Region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa)
Market Overview
The Global Companion Diagnostics Market was valued at USD 6,768.3 million in 2023 and is expected to reach USD 17,740.0 million by 2031 while growing at a CAGR of 12.8% during the forecast period (2024-2031).
*Note: Graph is shown for illustrative purposes only; complete datasets will be provided in the full report
Market Dynamics
This section of the report will analyze various driving and restraining factors that are expected to have a significant impact on the global companion diagnostics market growth. Companion diagnostics (CDx) are specialized in vitro diagnostic devices or tests designed to furnish crucial information necessary for the safe and efficient utilization of a corresponding therapeutic product, developed alongside specific drugs. They help identify patients who are most likely to benefit from treatment or assess the risk of adverse reactions to the medication.
Advancements in diagnostic technologies like genomics, proteomics, NGS, and molecular diagnostics are fueling the growth of the companion diagnostics market alongside the rising adoption of personalized medicine. Yet, cost constraints and regulatory challenges could hinder its expansion.
Furthermore, the global companion diagnostics industry will be analyzed through various tools including PESTLE analysis, and Porter’s analysis.
Segmentation – By Technology Analysis
The Global Companion Diagnostics Market is segmented among Immunohistochemistry (IHC), Polymerase Chain Reaction (PCR), In-situ Hybridization (ISH), Real-time PCR (RT-PCR), Gene Sequencing, and Other Technologies, based on Technology. In 2023, Polymerase Chain Reaction (PCR) accounted for the majority of the market share*.
*Note: Graph is shown for illustrative purposes only; complete datasets will be provided in the full report
Segmentation – By Indication Analysis
The Global Companion Diagnostics Market is segmented among Lung Cancer, Breast Cancer, Colorectal Cancer, Leukemia, Melanoma, and Other Indications, based on Indication. In 2023, Lung Cancer accounted for the majority of the market share*.
*Note: Graph is shown for illustrative purposes only; complete datasets will be provided in the full report
Global Companion Diagnostics Market: Regional Analysis
Based on region, the market is divided into six regions including North America, Europe, Asia Pacific, Latin America, Middle East, and Africa. In 2023, North America dominated the market with the highest market share, while Asia Pacific is expected to grow with the highest CAGR during the forecast period (2024 – 2031).
*Note: Graph is shown for illustrative purposes only; complete datasets will be provided in the full report
Competitive Landscape
Some of the key players operating in the market are Abbott Laboratories Inc., Agilent Technologies Inc., F.Hoffmann-La Roche Ltd, Biomerieux SA, Qiagen NV, Siemens Healthcare, Thermo Fisher Scientific Inc., Danaher Corporation (Beckman Coulter Inc.), Almac Group, and Illumina Inc.
Table of Contents:
1. Research Methodology and Market Scope
Research Methodology
Market Scope
2. Executive Summary
3. Global Companion Diagnostics Market Dynamics
Drivers
Restraints
Opportunity
4. Global Companion Diagnostics Industry Analysis
PEST Analysis
Porter's Five Force Analysis
Recent Deals Analysis
5. Global Companion Diagnostics Market Segmentation, By Technology
Global Companion Diagnostics Market Share Analysis, By Technology
Global Companion Diagnostics Market Growth Analysis, By Technology
Global Companion Diagnostics Market Trends, By Technology
o Immunohistochemistry (IHC)
o Polymerase Chain Reaction (PCR)
o In-situ Hybridization (ISH)
o Real-time PCR (RT-PCR)
o Gene Sequencing
o Other Technologies
6. Global Companion Diagnostics Market Segmentation, By Indication
Global Companion Diagnostics Market Share Analysis, By Indication
Global Companion Diagnostics Market Growth Analysis, By Indication
Global Companion Diagnostics Market Trends, By Indication
o Lung Cancer
o Breast Cancer
o Colorectal Cancer
o Leukemia
o Melanoma
o Other Indications
7. Global Companion Diagnostics Market Segmentation, By Region
Global Companion Diagnostics Market Share Analysis, By Region
Global Companion Diagnostics Market Growth Analysis, By Region
Global Companion Diagnostics Market Trends, By Region
o North America
o Europe
o Asia Pacific
o Latin America
o Middle East
o Africa
8. Competitive Landscape
Abbott Laboratories Inc.*
o Company Overview
o Financial Performance
o Key Development/Strategies
o SWOT Analysis
Agilent Technologies Inc.
F.Hoffmann-La Roche Ltd
Biomerieux SA
Qiagen NV
Siemens Healthcare
Thermo Fisher Scientific Inc.
Danaher Corporation (Beckman Coulter Inc.)
Almac Group
Illumina Inc.
*Similar analysis will be provided for each company listed above.
